Background: Secreted frizzled-related protein 5 (SFRP5) is an adipokine protecting against obesity-related insulin resistance and diabetes. SFRP5 binds to wingless type mouse mammary tumor virus (MMTV) integration site family member 5A (WNT5A) to improve insulin sensitivity. We performed the first study of SFRP5 and WNT5A simultaneously in children. Methods: Prepubertal children (n = 342) were assessed for circulating SFRP5 (all subjects) and circulating WNT5A (210 subjects), and associations were sought with metabolic markers. In conditioned media of adipose tissue explants from 12 additional children, SFRP5 and WNT5A were studied further. results: The concentrations of SFRP5 and WNT5A correlated positively in serum and in conditioned media (all P < 0.001). Lower level of circulating SFRP5 (lowest quartile) was associated with higher BMI (15% increase, P < 0.0001) and lower level of high-molecular-weight adiponectin (26% decrease, P = 0.002). Circulating WNT5A related closely with insulin resistance assessed by the homeostasis model assessment for insulin resistance and hepatic markers (alanine transaminase and gamma glutamyl transpeptidase), particularly in children with lower circulating SFRP5 levels (all P < 0.004). conclusion: SFRP5 and WNT5A comprise a balanced duo that may regulate metabolic homeostasis in prepubertal children. o besity is a common disorder that predisposes individuals to a number of metabolic abnormalities and is often associated with a low-grade inflammatory state in adipose tissue (1,2). Adipose tissue constitutes the body's largest endocrine organ, secreting a variety of cytokines, referred to as adipokines (3).
o besity is a common disorder that predisposes individuals to a number of metabolic abnormalities and is often associated with a low-grade inflammatory state in adipose tissue (1, 2) . Adipose tissue constitutes the body's largest endocrine organ, secreting a variety of cytokines, referred to as adipokines (3) .
Secreted frizzled-related protein 5 (SFRP5) is a recently described adipokine that has been associated with obesityrelated insulin resistance and type 2 diabetes (4) (5) (6) (7) (8) . Systemic administration of SFRP5 to animals lacking SFRP5 gene improved glucose tolerance and insulin sensitivity and diminished inflammation (5) . SFRP5 binds and sequesters wingless type mouse mammary tumor virus (MMTV) integration site family member 5A (WNT5A) in the adipose tissue extracellular space. The Wnt proteins are a family of secreted glycoproteins that signal through a cell surface receptor known as frizzled. WNT5A could act as an important proinflammatory factor by upregulating the serine-threonine kinase c-Jun N-terminal kinase 1 (9, 10) . It is believed that SFRP5 binding to WNT5A attenuates Wnt signaling (11, 12) , thereby restraining the chronic inflammatory state and improving insulin sensitivity (5) . Recent studies suggested that WNT5A could also play a role in the activation of hepatic stellate cells, which has been related to the development of liver disease associated with insulin resistance (13, 14) .
The SFRP5-WNT5A regulatory axis in fat may thus represent a potential target for the control of obesity-linked metabolic abnormalities (5) . In a first study in children, we hypothesized that low SFRP5 levels would be related to a lessfavorable metabolic phenotype and would potentiate the association of WNT5A with insulin resistance.
RESULTS
To ascertain whether SFRP5 was associated with metabolic risk markers in prepubertal children, the studied subjects were stratified according to SFRP5 quartiles ( Table 1) . In general linear models, after adjusting for age, gender, and BMI, there were statistically significant differences for a number of metabolic characteristics among the quartile groups. Subjects in the lowest quartile of serum SFRP5 exhibited higher systolic blood pressure-standard deviation score (SDS) (P = 0.001), diastolic blood pressure (DBP)-SDS (P = 0.007), carotid intima-media thickness (P < 0.05), triglyceride-to-highdensity lipoprotein ratio (P < 0.01), homeostasis model assessment for insulin resistance (HOMA-IR) (P = 0.025), leptin (P < 0.0001), and high-sensitivity C-reactive protein (P = 0.002) and lower levels of high-density-lipoprotein cholesterol (P < 0.05) and high-molecular-weight adiponectin (P = 0.002), Articles Prats-Puig et al.
compared with the levels in subjects in the highest quartile of serum SFRP5 (Table 1 ; Supplementary Figure S1 online). In multiple regression analyses, BMI-SDS and high-molecularweight adiponectin were independent predictors of SFRP5, together explaining 19.2% of its variance ( Table 2 ). The inclusion or exclusion of obese subjects did not change the results of our study, and no gender interactions were found in any of the above-mentioned associations (results not shown).
Decreased SFRP5 levels were also associated with a significant increase in the prevalence of obesity after adjusting for age and gender (prevalence of obesity ranged from 10.5% in the highest quartile to 43.6% in the lowest quartile of SFRP5; P < 0.0001). Consequently, children with lower levels of SFRP5 had an elevated odds ratio for obesity, after controlling for potential confounders (P < 0.0001; Supplementary Figure S2 online).
SFRP5 and WNT5A protein levels were highly positively correlated (P < 0.0001) in serum from the studied subjects (n = 210) and in conditioned media from samples of visceral and subcutaneous adipose tissue (n = 12; Supplementary  Figure S3 online). The association between WNT5A and metabolic risk markers was therefore examined in children with lower and higher serum SFRP5 concentrations.
Serum WNT5A was related to higher insulin resistance (HOMA-IR: r = 0.236, P < 0.001) and hepatic markers (alanine transaminase (ALT): r = 0.127, P < 0.05) in prepubertal children. In children with lower SFRP5, WNT5A was strongly associated with (i) insulin resistance (HOMA-IR: r = 0.339, P < 0.001) and (ii) hepatic markers (ALT: r = 0.344, P < 0.0001; and gamma glutamyl transpeptidase: r = 0.264, P < 0.001), which was not apparent in children with higher SFRP5 concentrations ( Table 3) . No gender interactions were found in these associations (data not shown).
In multiple regression analyses, BMI-SDS and WNT5A were independently related to HOMA-IR and ALT ( Table 4) .
DISCUSSION
Ours is the first report associating decreased concentrations of SFRP5 with obesity markers and lower level of high-molecular-weight adiponectin in prepubertal children. We also report that lower serum SFRP5 potentiated the association between WNT5A and insulin resistance. SFRP5 is a recently described adipokine that has been associated with obesity-related insulin resistance and type 2 diabetes (4) (5) (6) 8) . A recent study showed that circulating SFRP5 was decreased in patients with impaired glucose tolerance or type 2 diabetes and was associated with various obesity-related metabolic parameters (4,7). SFRP5 sequesters WNT5A, thereby attenuating the activation of c-Jun N-terminal kinase 1 (9,10). Our results suggest that SFRP5 may be an anti-inflammatory adipokine that could be negatively regulated during obesity development, leading to a less-favorable metabolic phenotype. For some of the metabolic parameters studied, the results may be indicative of a threshold effect, with a poorer metabolic profile restricted to subjects within the lower SFRP5 quartile.
We also describe that WNT5A was positively related to SFRP5 in both serum and conditioned media of adipose tissue explants. In children with lower SFRP5 serum levels, WNT5A was more strongly related to insulin resistance and hepatic markers, which fits with the known proinflammatory action of WNT5A on preadipocyte cells, preventing their differentiation and leading to insulin resistance (15) . These results suggest that a failure to upregulate SFRP5 in obesity may lead to unrestrained proinflammatory actions of WNT5A, resulting in metabolic dysfunction (5, 6) . It is well established that the inability to store the excess of energy in adipose tissue contributes to ectopic lipid accumulation in the liver (16) . A recent study also reported that WNT5A is involved in the activation of hepatic stellate cells, which in turn is implicated in nonalcoholic fatty liver disease (13) .
In our study, SFRP5 levels decreased with age in prepubertal children. It is well established that levels of adipokines such as adiponectin, a bona fide anti-inflammatory adipokine, decline in parallel with age and pubertal development in association with changes in growth factors (17) and androgen levels (18). Similarly, increased leptin level during puberty is a reliable indicator of insulin resistance associated with increasing age (19) . Thus, we cannot exclude the possibility that reduced SFRP5 levels may contribute to the state of insulin resistance associated with increasing age and pubertal development (20) . However, mores studies are needed in pubertal children to ascertain the influence of age and puberty on SFRP5 levels.
To the best of our knowledge, this is the first article to study SFRP5 and WNT5A simultaneously and the interaction thereof with metabolic risk markers, and this is also the first description in children in whom the metabolic abnormalities associated with obesity are known to originate. We acknowledge that our findings need to be corroborated in other populations and that longitudinal studies are warranted to disclose whether children with low levels of SFRP5 and/or unrestrained levels of WNT5A may be more likely to develop obesity-related metabolic dysfunction.
In summary, this exploratory study illustrates that SFRP5 and WNT5A comprise a balanced duo that may regulate metabolic homeostasis in prepubertal children. SFRP5 is a putative anti-inflammatory adipokine that could, at least in part, restrain the proinflammatory effects of WNT5A in children.
METHODS

Population and Ethics
Subjects were 342 school-aged Caucasian children (179 boys and 163 girls; age: 7.2 ± 0.1 y) included in an ongoing study of cardiovascular risk factors in prepubertal children. Subjects were consecutively (21) . Inclusion criteria were (i) age between 5 and 10 y and (ii) no pubertal development, as judged by a specifically trained nurse using Tanner criteria (breast stage I; testicular volume < 4 ml). Exclusion criteria were (i) major congenital abnormalities; (ii) abnormal blood counts and abnormal liver, kidney, or thyroid functions; (iii) evidence of chronic illness or chronic use of medication; (iv) acute illness or use of medication in the month preceding potential enrollment; and (v) malnutrition, defined as BMI-SDS ≤ −2.
The research was approved by the Institutional Review Board of Dr Josep Trueta Hospital. Signed consent was obtained from the parents.
Clinical Assessments
Clinical examination was performed in the morning, in the fasting state, followed by venous blood sampling. Weight was measured wearing light clothes with a calibrated scale, and height was measured with a Harpenden stadiometer. BMI was calculated as weight divided by the square of height in meters. Waist circumference was measured in the supine position at the umbilical level. Age-and sex-adjusted SDSs for BMI and waist circumference were calculated using regional normative data. Childhood obesity was defined as BMI-SDS ≥ 2.
Blood pressure was measured in the supine position on the right arm after a 10-min rest; an electronic sphygmomanometer with cuff size appropriate for arm circumference was used. Age-and sexadjusted SDSs for waist circumference and blood pressure were calculated using our population data.
High-Resolution Ultrasound Measurements
Carotid intima-media thickness was measured by high-resolution ultrasonography. Diastolic images were obtained using a linear 12-MHz transducer on the right side at the level of the distal common carotid artery, 1 cm away from its bifurcation point. Averages of five measurements of the carotid intima-media thickness on the far wall of the artery were used in the study. All measurements were taken on a separate visit in all children and were performed by the same observer who was unaware of the clinical and laboratory characteristics of the subjects. Intrasubject coefficient of variation (CV) for ultrasound measurements was <6%. None of the children in our study showed ultrasonographic signs of atherosclerotic plaques.
Laboratory Variables
All serum samples were obtained between 8:00 and 9:00 am under fasting conditions. Serum glucose was analyzed by the glucose hexoquinase method. Serum immunoreactive insulin was measured by immunochemiluminescence. Lower detection limit was 0.4 mIU/l and intra-and interassay CVs were <10%. Insulin resistance was calculated using the HOMA-IR (HOMA-IR = (fasting insulin, in mU/l) × (fasting glucose, in mmol/l)/22.5). High-density-lipoprotein cholesterol was quantified by homogenous method of selective detergent with accelerator. Total serum triglycerides were measured by monitoring the reaction of glycerol phosphate oxidase. Serum aspartate transaminase, ALT, and gamma glutamyl transpeptidase were measured by colorimetry using automated tests. Intra-and interassay CVs were <4% for these tests. Serum levels of high-sensitivity C-reactive protein were measured using the ultrasensitive latex immunoassay CRP Vario (Sentinel Diagnostics, Milan, Italy). Lower detection limit was 0.2 mg/l, and the intra-and interassay CVs were <3%. All values <0.2 mg/l were coded as 0.2. Children with highsensitivity C-reactive protein values >10.0 mg/l were excluded from the study.
High-molecular-weight adiponectin was measured by sandwich enzyme-linked immunosorbent assay (Linco, St Charles, MO), the detection limit was 0.5 ng/ml, and the CV was <4%. Leptin was measured by sandwich enzyme-linked immunosorbent assay (Linco), the detection limit was 0.2 ng/ml, and the CV was <3%. SFRP5 and WNT5A were measured by sandwich enzyme immunoassays (Uscn Life Science, Wuhan, People's Republic of China), with sensitivities of 0.55 and 0.053 ng/ml, respectively. CVs at our laboratory were <6%. The leptin and WNT5A assessments were limited to a representative randomly selected sample of the studied subjects whose clinical characteristics did not diverge from those of the whole group (n = 210; 115 boys and 95 girls).
Adipose Tissue Explants
Samples of visceral and subcutaneous adipose tissue biopsies were obtained after obtaining written informed consent from 12 additional children (10 boys and 2 girls, age: 6.1 ± 1.3 y) undergoing abdominal surgery for urological malformations or repair of inguinal hernia. All subjects were otherwise asymptomatic (they were free from any acute or chronic illness) and had normal blood counts and normal liver and kidney functions. Adipose tissue biopsies were cut into small pieces and washed in PBS with 5% bovine serum albumin for 30 min at room temperature. Explants were incubated (~300 mg of tissue per well) in 12-well plates with 1 ml Dulbecco's modified essential medium supplemented with 1% sodium pyruvate, 1% glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin for up to 48 h at 37 ºC in 5% CO 2 . Conditioned media were collected for studies of concentrations of total protein, SFRP5, and WNT5A at 48 h.
Both SFRP5 and WNT5A were measured in conditioned media using the same commercial assays as described above. Results were adjusted for the sum of total protein concentration in conditioned media and in tissue lysate, as measured by the Lowry method (22) .
Assessment of Viability of Adipose Tissue Explants
Viability of adipose tissue explants was assessed by measuring lactate dehydrogenase activity in conditioned media. To prepare for the lactate dehydrogenase assay, the conditioned medium of adipose tissue was transferred to a 1.5-ml microcentrifuge tube and centrifuged at 12,000g and 4 ºC for 15 min to remove cell debris.
Measurement of total lactate dehydrogenase activity in the samples was obtained by the International Federation of Clinical Chemistry and Laboratory Medicine-recommended forward reaction (23) , which catalyzes the oxidation of l-lactate to pyruvate with the mediation of oxidized nicotinamide adenine dinucleotide as a hydrogen acceptor (Architect, Abbott Diagnostics, Milan, Italy). Intra-and interassay CVs were <4.7% for this test. Results were adjusted for the sum of total protein concentration in conditioned media and in tissue lysate, as measured by the Lowry method (22) .
Statistics
Statistical analyses were performed using SPSS version 12.0. Results are expressed as mean and 95% CI. Nonparametric variables were logarithmically transformed to improve symmetry. Differences among SFRP5 quartiles in children were evaluated using general linear models after adjusting for age, gender, and BMI. Partial correlation followed by multiple regression analyses were used to analyze the associations of SFRP5 and WNT5A with metabolic parameters. The enter method was used for computing the independent variables. Logistic regression analyses were used to identify independent associations between SFRP5 quartiles and obesity. Significance level was set at P < 0.05. The sample size was calculated to have 80% power to detect significant correlations between circulating SFRP5 or WNT5A and metabolic risk markers, with a Pearson correlation coefficient of at least 0.30 in both total and subgroups analyses (n = 84 would be the minimum sample size in subgroup analyses in order to detect such correlations in bilateral tests).
